Asciminib resistance treatment

Asciminib (Asciminib) is a drug used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML) with the trade name Scemblix. Aceminib is a protein kinase inhibitor. The most common adverse reactions include upper respiratory tract infection, musculoskeletal pain, fatigue, nausea, rash and diarrhea. The treatment method for aximinib resistance needs to be formulated according to the specific situation of the patient. It needs to comprehensively consider the patient's condition, physical condition, degree of resistance and other factors, and be evaluated and treated by a doctor.

Aceminib is a commonly used anti-tumor drug. If resistance occurs, other drugs can be considered for treatment, such as other targeted drugs or chemotherapy drugs. Combination treatment methods can also be used to improve the efficacy. If resistance is not severe, the dose of aceminib may be adjusted to enhance efficacy. Depending on the patient's specific circumstances, a change in treatment may be attempted, such as a different combination of medications or a new treatment approach. At the same time, patients should actively cooperate with doctors’ treatment suggestions, maintain a good attitude, and actively face the disease.

The original drug of Asiminib has not yet been launched in China, so it cannot be included in medical insurance. The original drug of Asiminib currently sold overseas is very expensive. Generic drugs of Asiminil are also produced and marketed overseas, and their drug ingredients are basically the same as those of the original drug. For example, the price of 40mg*60 tablets produced by a Laos pharmaceutical factory may be more than 4,000 yuan per box (the price may fluctuate due to exchange rate effects), and the price is relatively cheap. For more drug information and specific prices, please consult Yaode’s medical consultant.